A Research presented during the American Association for Geriatric Psychiatry (AAGP) 2014 Annual Meeting found that 8,285 out of a million men who took Risperdal developed gynecomastia, or male breast growth. The report confirmed that gynecomastia was a potential side effect of Risperdal in adult men, but the drug has also come under fire for its side effects in a more susceptible group.
Ortho McNeil Janssen, a division of Johnson and Johnson (J&J), ordered its sales representatives to visit kid psychologists and mental health facilities to endorse Risperdal as a safe treatment for behavior disorders such as attention shortfall hyperactivity disorder (ADHD) and obsessive compulsive disorder (OCD), according to the New York Times. You can also hire risperdal gynecomastia attorneys to claim the Risperdal Gynecomastia Settlement Amounts.
Federal officials claim that J&J knew children were more vulnerable to Risperdal gynecomastia risks, but failed to appropriately warn the public about Risperdal side effects in children, the New York Times also reported. Hundreds of unwary boys who took Risperdal and developed gynecomastia have filed Risperdal lawsuits looking for compensation for medical expenses counting gynecomastia surgery costs.
In November 2013, Johnson & Johnson (J&J) agreed to pay $2.2 billion in criminal and civil fines to settle allegations that it improperly marketed Risperdal to children, older adults and folks with developmental delays.
New research presented at the American Association for Geriatric Psychiatry (AAGP) 2014 Annual Meeting seems to substantiate the link between Johnson & Johnson’s drug Risperdal and gynecomastia, the growth of breasts in men and young boys in a condition being referred to as Risperdal Gynecomastia.
The research was presented by Dr. Mahyar Etminan, a prominent pharmaceopidemiologist and lead investigator at the University of British Columbia. The team of researchers studied tens of thousands of patients to inspect side effects of the popular antipsychotic drugs Risperdal and Invega.
They found astonishingly high increase in the risk of abnormal breast growth (gynecomastia) in patients who took the drugs. Compared with patients who were not taking the drug, older men taking Risperdal were found to have had a 69 percent higher probability of abnormal breast growth.
While former research studies done on animals about the safety of Risperdal also specified a link between the hormone prolactin (which is responsible for breast growth) and the drug, this significant research from Dr. Etminan’s team at the University of British Columbia has proven the link in humans.